Covid-19 manufacturing roundup: Catalent adds freezer partner for vaccine production push; In need of volunteers, Lonza turns to food workers
As Catalent ramps up its production of Covid-19 vaccines in a recent push to double its production, it has secured more of the technology to store them.
Catalent and Sterling will work together to provide more ultra-low temperature freezers for the CDMO to preserve highly temperature-sensitive material used in vaccines. The partnership has already resulted in the installation of over 200 freezers at Catalent facilities with plans for another 60 to be installed at cell and gene therapy sites across the US, Europe and Asia.
The freezers can operate at temperatures as low as -86 degrees Celsius and as high as -20 degrees Celsius.
The freezers use 100% natural refrigerants and will produce 30% of the carbon dioxide over a 10-year span than a typical freezer would produce, the company said. The Athens, OH-based company also claims the industry’s only portable solution for remote clinical trials and drug delivery.
On Thursday, Moderna announced that it would expand production of its mRNA-based Covid-19 vaccines at several of its facilities, including Catalent’s, in an effort to keep up with virus variants and provide doses to countries in need. One of the issues it faces is keeping the vaccine cold enough — at least -20 degrees Celsius — while delivering the vaccines to countries that do not have easy access to modern refrigeration devices.
In need of volunteers, Lonza turns to food workers to help make vaccine
As a number of companies have pledged to ramp up Covid-19 vaccines following recent second waves around the world, drugmakers are in need of employees to help speed up production.
In Switzerland, Lonza has recruited staff from food giant Nestle to make ingredients, according to Reuters.
Moderna recently announced that it would double the vaccine production at several of its plants, and Lonza’s site in Visp is one of them. Last week, the company blamed delays in shipments on production bottlenecks. Employees at a western Switzerland Nestle research center were asked a week ago to volunteer to step into the vaccine manufacturing world for a three-month mission, Reuters said.